Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levofloxacin
Drug ID BADD_D01275
Description Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin].[A190663] It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin[A190663] and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer).[L11638] Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663]
Indications and Usage In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate.[L11638,L11692] The oral formulation is also indicated in both adults and children 6 months of age and older for the post-exposure management of inhalational anthrax caused by _Bacillus anthracis_ and for the treatment and/or prophylaxis of plague caused by _Yersinia pestis_.[L11638] In its ophthalmic formulation, levofloxacin is indicated for the treatment of bacterial conjunctivitis caused by susceptible organisms.[L11641] An inhalational solution available in Canada is indicated for the management of cystic fibrosis patients aged 18 years or older with chronic pulmonary _Pseudomonas aeruginosa_ infections.[L11689]
Marketing Status approved; investigational
ATC Code J01MA12; S01AE05
DrugBank ID DB01137
KEGG ID D00588; D08120
MeSH ID D064704
PubChem ID 149096
TTD Drug ID D02RSN
NDC Product Code 0904-6353; 31722-723; 33342-532; 36000-294; 43063-457; 43063-637; 54288-140; 63187-004; 63187-384; 63187-438; 63187-514; 65841-693; 67296-1546; 70518-0968; 70518-3712; 72189-338; 0904-6352; 49587-102; 17478-107; 36000-045; 45865-758; 55154-5898; 63187-833; 63323-355; 68788-8340; 71335-0434; 72578-098; 0781-5791; 80425-0007; 80425-0008; 80425-0009; 82982-034; 53104-7550; 63415-0056; 33342-022; 36000-296; 0143-9720; 50090-4572; 51655-666; 61919-440; 61919-704; 67296-0744; 67296-0897; 67296-1393; 0409-0528; 70771-1079; 71205-058; 55111-281; 65841-691; 65862-537; 68083-416; 68180-242; 68382-989; 69097-287; 0527-1948; 70518-0453; 71335-0794; 53069-0600; 65862-488; 31722-721; 33342-021; 0143-9317; 43063-638; 67296-0972; 67296-0977; 67296-1400; 68071-3236; 68083-415; 70518-0719; 71335-0593; 72578-099; 0904-6351; 65862-536; 0143-9316; 50383-286; 70934-094; 71335-1208; 65862-538; 16571-150; 25021-132; 33342-023; 33342-531; 36000-048; 44567-436; 50090-3314; 51655-947; 55111-279; 63187-925; 67296-1325; 67296-1351; 67296-1535; 68071-4512; 68083-395; 68180-241; 70518-0587; 0781-5790; 0781-5792; 43235-0007; 31722-722; 36000-046; 43063-796; 0143-9721; 51407-428; 67296-0975; 67296-0985; 71205-002; 71205-234; 71335-0380; 72789-085; 72789-248; 17478-106; 0143-9315; 44567-437; 50090-4797; 53002-1350; 55111-280; 55150-156; 55150-157; 63187-003; 68083-414; 68788-6938; 72578-100; 80425-0077; 55525-0001; 36000-295; 44567-435; 50090-3214; 50090-3311; 51407-429; 51655-327; 61919-426; 65841-692; 68083-394; 68180-240; 80425-0076; 65977-0039; 33342-533; 36000-047; 42571-168; 43063-459; 0143-9722; 51407-430; 53002-2350; 55154-5897; 55700-729
UNII 6GNT3Y5LMF
Synonyms Levofloxacin | Ofloxacin, (S)-Isomer | Levofloxacin Anhydrous | Anhydrous, Levofloxacin | Quixin | Levaquin
Chemical Information
Molecular Formula C18H20FN3O4
CAS Registry Number 100986-85-4
SMILES CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Inflammatory pain08.01.08.0280.000093%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000084%Not Available
Cerebral calcification17.11.01.0120.000042%Not Available
Fear of death19.06.03.0060.000042%Not Available
Weight bearing difficulty15.03.05.0340.000105%Not Available
Abdominal wall haematoma24.07.02.039; 07.16.05.0050.000211%Not Available
Apparent death08.01.03.0620.000042%Not Available
Skin plaque23.03.03.0440.000042%Not Available
Ocular pemphigoid23.03.01.030; 10.04.04.015; 06.04.05.0300.000063%Not Available
Capillaritis24.12.04.004; 23.06.02.0070.000042%Not Available
Respiratory fatigue22.02.01.0420.000042%Not Available
Ligament pain15.07.02.0070.000093%Not Available
Tubulointerstitial nephritis and uveitis syndrome20.05.02.004; 10.02.01.065; 06.04.03.0060.000063%Not Available
Band sensation17.16.01.0040.000127%Not Available
Respiratory muscle weakness22.09.01.004; 17.05.03.017; 15.05.06.0030.000148%Not Available
Crystal nephropathy20.05.03.016; 14.11.01.0350.000274%Not Available
Hyporesponsive to stimuli17.02.05.0570.000063%Not Available
Spinal pain15.02.01.008; 08.01.08.030; 17.10.01.0200.000105%Not Available
Chronic spontaneous urticaria23.04.02.011; 10.01.06.011--Not Available
Fat tissue decreased08.01.03.0680.000042%Not Available
Postural tremor17.01.06.0090.000084%Not Available
Small fibre neuropathy14.07.04.007; 17.09.03.021; 05.07.04.0070.000042%Not Available
Tendon discomfort15.07.01.0120.000388%Not Available
Nodular rash23.03.13.0210.000105%Not Available
Urinary tract discomfort20.02.03.0170.000105%Not Available
Lacunar stroke24.04.06.037; 17.08.01.0540.000105%Not Available
Primary myelofibrosis16.21.03.008; 01.13.03.0080.000042%Not Available
Administration site erythema23.03.06.021; 12.07.04.018; 08.02.04.0180.000063%Not Available
Administration site oedema12.07.04.028; 08.02.04.0280.000063%Not Available
Attention deficit hyperactivity disorder19.21.04.0040.000063%Not Available
The 27th Page    First    Pre   27 28 29    Next   Last    Total 29 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene